Caspofungin in the treatment of invasive fungal infections.
Caspofungin is a member of a new class of antifungals called Echinocandins and is the first to have marketing authorisation in the United Kingdom. This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of caspofungin. The article also discusses the warnings and precautions associated with the use of this drug. Caspofungin is an effective treatment option in the management of fungal infections.
Keady
Simon
S
Women and Children's Services, University College London Hospitals NHS Foundation Trust, UK. simon.keady@uclh.nhs.uk
Thacker
Meera
M
D000935:Antifungal Agents / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D000077336:Caspofungin; D004334:Drug Administration Schedule; D017277:Drug Approval; D004347:Drug Interactions; D016903:Drug Monitoring; D054714:Echinocandins; D006801:Humans; D055666:Lipopeptides; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D018579:Patient Selection; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D016896:Treatment Outcome; D006113:United Kingdom
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin